Massimiliano Donzelli1, Adrian Derungs2, Maria-Giovanna Serratore3, Christoph Noppen3, Lana Nezic1, Stephan Krähenbühl1, Manuel Haschke4,5. 1. Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University of Basel, Basel, Switzerland. 2. Division of Clinical Pharmacology and Toxicology, Inselspital Bern, Bern, Switzerland. 3. Viollier AG, Allschwil, Switzerland. 4. Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University of Basel, Basel, Switzerland. manuel.haschke@unibas.ch. 5. Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Hebelstrasse 2, 4031, Basel, Switzerland. manuel.haschke@unibas.ch.
Abstract
BACKGROUND AND OBJECTIVE: Phenotyping cocktails use a combination of cytochrome P450 (CYP)-specific probe drugs to simultaneously assess the activity of different CYP isoforms. To improve the clinical applicability of CYP phenotyping, the main objectives of this study were to develop a new cocktail based on probe drugs that are widely used in clinical practice and to test whether alternative sampling methods such as collection of dried blood spots (DBS) or saliva could be used to simplify the sampling process. METHODS: In a randomized crossover study, a new combination of commercially available probe drugs (the Basel cocktail) was tested for simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Sixteen subjects received low doses of caffeine, efavirenz, losartan, omeprazole, metoprolol and midazolam in different combinations. All subjects were genotyped, and full pharmacokinetic profiles of the probe drugs and their main metabolites were determined in plasma, dried blood spots and saliva samples. RESULTS: The Basel cocktail was well tolerated, and bioequivalence tests showed no evidence of mutual interactions between the probe drugs. In plasma, single timepoint metabolic ratios at 2 h (for CYP2C19 and CYP3A4) or at 8 h (for the other isoforms) after dosing showed high correlations with corresponding area under the concentration-time curve (AUC) ratios (AUC0-24h parent/AUC0-24h metabolite) and are proposed as simple phenotyping metrics. Metabolic ratios in dried blood spots (for CYP1A2 and CYP2C19) or in saliva samples (for CYP1A2) were comparable to plasma ratios and offer the option of minimally invasive or non-invasive phenotyping of these isoforms. CONCLUSIONS: This new combination of phenotyping probe drugs can be used without mutual interactions. The proposed sampling timepoints have the potential to facilitate clinical application of phenotyping but require further validation in conditions of altered CYP activity. The use of DBS or saliva samples seems feasible for phenotyping of the selected CYP isoforms.
RCT Entities:
BACKGROUND AND OBJECTIVE: Phenotyping cocktails use a combination of cytochrome P450 (CYP)-specific probe drugs to simultaneously assess the activity of different CYP isoforms. To improve the clinical applicability of CYP phenotyping, the main objectives of this study were to develop a new cocktail based on probe drugs that are widely used in clinical practice and to test whether alternative sampling methods such as collection of dried blood spots (DBS) or saliva could be used to simplify the sampling process. METHODS: In a randomized crossover study, a new combination of commercially available probe drugs (the Basel cocktail) was tested for simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Sixteen subjects received low doses of caffeine, efavirenz, losartan, omeprazole, metoprolol and midazolam in different combinations. All subjects were genotyped, and full pharmacokinetic profiles of the probe drugs and their main metabolites were determined in plasma, dried blood spots and saliva samples. RESULTS: The Basel cocktail was well tolerated, and bioequivalence tests showed no evidence of mutual interactions between the probe drugs. In plasma, single timepoint metabolic ratios at 2 h (for CYP2C19 and CYP3A4) or at 8 h (for the other isoforms) after dosing showed high correlations with corresponding area under the concentration-time curve (AUC) ratios (AUC0-24h parent/AUC0-24h metabolite) and are proposed as simple phenotyping metrics. Metabolic ratios in dried blood spots (for CYP1A2 and CYP2C19) or in saliva samples (for CYP1A2) were comparable to plasma ratios and offer the option of minimally invasive or non-invasive phenotyping of these isoforms. CONCLUSIONS: This new combination of phenotyping probe drugs can be used without mutual interactions. The proposed sampling timepoints have the potential to facilitate clinical application of phenotyping but require further validation in conditions of altered CYP activity. The use of DBS or saliva samples seems feasible for phenotyping of the selected CYP isoforms.
Authors: Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta Journal: J Pharmacol Exp Ther Date: 2003-04-03 Impact factor: 4.030
Authors: Y Daali; C Samer; J Déglon; A Thomas; J Chabert; M Rebsamen; C Staub; P Dayer; J Desmeules Journal: Clin Pharmacol Ther Date: 2012-01-11 Impact factor: 6.875
Authors: Magnus Christensen; Katarina Andersson; Per Dalén; Rajaa A Mirghani; Gary J Muirhead; Anna Nordmark; Gunnel Tybring; Anneli Wahlberg; Umit Yaşar; Leif Bertilsson Journal: Clin Pharmacol Ther Date: 2003-06 Impact factor: 6.875
Authors: Siwaporn Chainuvati; Anne N Nafziger; J Steven Leeder; Andrea Gaedigk; Gregory L Kearns; Edward Sellers; Yanhua Zhang; Angela D M Kashuba; Elizabeth Rowland; Joseph S Bertino Journal: Clin Pharmacol Ther Date: 2003-11 Impact factor: 6.875
Authors: Adrian Derungs; Massimiliano Donzelli; Benjamin Berger; Christoph Noppen; Stephan Krähenbühl; Manuel Haschke Journal: Clin Pharmacokinet Date: 2016-01 Impact factor: 6.447
Authors: Benjamin Berger; Massimiliano Donzelli; Swarna Maseneni; Franziska Boess; Adrian Roth; Stephan Krähenbühl; Manuel Haschke Journal: Front Pharmacol Date: 2016-11-21 Impact factor: 5.810